Availability
0
Your Basket is Empty
BS166446

Sitravatinib - Bio-X

Inhibits multiple receptor tyrosine kinases (RTKs), including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl. Sitravatinib inhibits proliferation of sarcoma cells and reduced tumor growth in vivo. Promotes immune response in tumor microenvironment and enhances sensitivity to immune checkpoint inhibitors. This compound is undergoing several clinical trials as a potential anti-cancer therapeutic agent.

Technical Data

CAS No: 1123837-84-2
Synonyms: MGCD516
Product Code: BS166446
Chemical Formula: C33H29F2N5O4S
Molecular Weight: 629.68

References


  • PP Patwardhan et al (2016). Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 7(4):4093-109.
  • Du W et al (2018). Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight 3(21) pii: 124184.

Solubility

Stability

Further Information


Datasheets


Sitravatinib - Bio-X

CAS No:
1123837-84-2
Synonyms:
MGCD516
Chemical Formula:
Molecular Weight:
629.68
Product Structure
References:
1. PP Patwardhan et al (2016). Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 7(4):4093-109.
2. Du W et al (2018). Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. JCI Insight 3(21) pii: 124184.

For requirements greater than the catalogue prepacks email: enquiries@carbosynth.com

Custom Synthesis

For custom synthesis or special requests email: enquiries@carbosynth.com, call +44 (0)1635 578444 or fill out our contact form

Please Wait...